Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 690 participants.
Also called NCT01560624
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 690 participants
- Sponsor
- Registry
-
NCT01560624
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Mexico, Netherlands, Poland, Singapore, South Korea, Sweden, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01560624. Randomized; quadruple masking; primary purpose treatment. Start 2012-06-26 (actual); primary completion 2018-06-24 (actual). Results posted on 2020-02-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
- Acronym
- FREEDOM-EV
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Treprostinil Diolamine
- Intervention (Drug)
- Placebo
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct01560624- Content hash
b63256ed1d7e3ec9663d987d3a9943028604a4e6dd423509ac2717014bee6755